Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Vidofludimus calcium offers a novel approach by combining two mechanisms – Nurr1 activation and DHODH inhibition. This dual action not only targets inflammatory and antiviral processes ...

Besides its effect on pathogenic immune cells, preclinical evidence further suggests a neuroprotective role of vidofludimus calcium via activation of Nurr1. Preclinical data support Nurr1-driven ...

Analyst William Wood from B.Riley Financial reiterated a Buy rating on Immunic (IMUX – Research Report) and keeping the price target at ...

nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium's (IMU-838) therapeutic potential in multiple sclerosis (MS). Key Insights Given the large stake in the stock by institutions, ...

The firm believes that vido's mechanism, which includes dihydroorotate dehydrogenase (DHODH) inhibition along with Nurr1 activation, offers additional benefits. Nurr1 activation is noted for its ...

Vidofludimus calcium is unique in its dual mechanism of action, combining Nurr1 activation with DHODH inhibition, which could offer both anti-inflammatory and neuroprotective benefits. Furthermore ...

Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic ? ? In Addition to Post COVID Readouts, ...

Here, the authors show that Nurr1 is important for maintaining neuron identity and receptor expression linked to hallucinatory states in this region. Empathy and aggression are essential to well ...

nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium's (IMU-838) therapeutic potential in multiple sclerosis (MS). Key Insights Given the large stake in the stock by institutions ...